We are live on
!
Find out more
BAMS
Bellevue Asset Management (Switzerland) Portfolio holdings
AUM
$656M
1-Year Est. Return
11.45%
This Fund
S&P 500
This Quarter
Est. Return
+12.15%
1 Year Est. Return
+11.45%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$717M
AUM Growth
–
Cap. Flow
+$692M
Cap. Flow
% of AUM
96.53%
Top 10 Holdings %
Top 10 Hldgs %
28.85%
Holding
141
New
141
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$27.9M |
| 2 |
CELG
Celgene Corp
CELG
|
+$27M |
| 3 |
Medtronic
MDT
|
+$25.8M |
| 4 |
Gilead Sciences
GILD
|
+$23.7M |
| 5 |
Abbott
ABT
|
+$23.3M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.25% |
| 2 | Financials | 0.88% |
| 3 | Industrials | 0.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
THOR
76
DELISTED
THORATEC CORPORATION
THOR
| $2.3M | 0.32% |
+55,000
| New | +$2.1M |
|
77
Merck
MRK
$322B
| $2.3M | 0.32% |
+41,920
| New | +$2.37M |
|
|
INFI
78
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $2.29M | 0.32% |
+164,000
| New | +$2.51M |
|
79
Globus Medical
GMED
$11.5B
| $2.27M | 0.32% |
+90,000
| New | +$2.19M |
|
|
ATHN
80
DELISTED
Athenahealth, Inc.
ATHN
| $2.15M | 0.3% |
+18,000
| New | +$2.4M |
|
81
Dentsply Sirona
XRAY
$2.34B
| $2.14M | 0.3% |
+42,000
| New | +$2.17M |
|
82
DaVita
DVA
$11.7B
| $2.11M | 0.29% |
+26,000
| New | +$2M |
|
|
NUVA
83
DELISTED
NuVasive, Inc.
NUVA
| $2.07M | 0.29% |
+45,000
| New | +$2.09M |
|
84
Edwards Lifesciences
EW
$53.3B
| $2.07M | 0.29% |
+87,000
| New | +$1.95M |
|
85
iShares Biotechnology ETF
IBB
$9.86B
| $2.06M | 0.29% |
+18,000
| New | +$1.99M |
|
|
RLYP
86
DELISTED
RELYPSA INC COM
RLYP
| $1.98M | 0.28% |
+55,000
| New | +$1.98M |
|
|
MDCO
87
DELISTED
Medicines Co
MDCO
| $1.96M | 0.27% |
+70,000
| New | +$1.97M |
|
|
HTWR
88
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
| $1.93M | 0.27% |
+22,000
| New | +$1.87M |
|
|
XENT
89
DELISTED
Intersect ENT, Inc
XENT
| $1.91M | 0.27% |
+73,800
| New | +$1.69M |
|
90
Steris
STE
$23.2B
| $1.9M | 0.26% |
+27,000
| New | +$1.78M |
|
|
ICPT
91
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $1.83M | 0.26% |
+6,500
| New | +$1.41M |
|
92
AngioDynamics
ANGO
$653M
| $1.78M | 0.25% |
+100,000
| New | +$1.86M |
|
|
OCR
93
DELISTED
OMNICARE INC
OCR
| $1.77M | 0.25% |
+23,000
| New | +$1.75M |
|
94
AbbVie
ABBV
$438B
| $1.76M | 0.25% |
+30,000
| New | +$1.81M |
|
95
Insulet
PODD
$9.88B
| $1.75M | 0.24% |
+52,500
| New | +$1.77M |
|
96
Thermo Fisher Scientific
TMO
$221B
| $1.75M | 0.24% |
+13,000
| New | +$1.68M |
|
|
BLUE
97
DELISTED
bluebird bio
BLUE
| $1.69M | 0.24% |
+1,081
| New | +$1.43M |
|
|
MASI
98
DELISTED
Masimo
MASI
| $1.65M | 0.23% |
+50,000
| New | +$1.44M |
|
99
Danaher
DHR
$146B
| $1.61M | 0.23% |
+28,269
| New | +$1.62M |
|
100
United Therapeutics
UTHR
$22.6B
| $1.6M | 0.22% |
+9,300
| New | +$1.42M |
|
Similar funds
VFAM
MSU
PSI
SFP
MCM
NMIS
SM
ZAM
Bellevue Asset Management (Switzerland)'s Q1 2015 Portfolio in Review
Q1 2015 is the first quarter with a 13F filing on record for Bellevue Asset Management (Switzerland), which disclosed 141 positions worth $717M. Its ten largest holdings account for 29% of the portfolio.
Its largest position is Biogen: 70,730 shares worth $29.9M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, followed by Financials and Industrials.
- Bellevue Asset Management (Switzerland)'s largest Q1 2015 buy was Biogen: 70,730 shares worth $29.9M.
- Bellevue Asset Management (Switzerland)'s ten largest holdings make up 29% of its $717M portfolio in Q1 2015.
- Bellevue Asset Management (Switzerland) disclosed 141 positions in Q1 2015, its first 13F filing on record.
Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q1 2015, filed 14 May 2015.